Innovacell Inc. Stock

504A

JP3147850006

Pharmaceuticals

Delayed Japan Exchange 02:30:00 2026-08-19 EDT			5-day change	1st Jan Change
601.00 ^JPY	+1.52%		+2.21%	-

08-06	Innovacell Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Innovacell Inc. Provides Update on ICEF15 Multi-Regional Phase III Clinical Trial Enrollment and Completion of Patient Recruitment in Japan and Europe	CI

Innovacell Inc a Japan-based company mainly develops and manufactures regenerative medicine products targeting fecal and urinary incontinence. The Company operates through a single segment named Cell Therapy and Regenerative Medicine Research and Development. Its business model is a global aggregation model, where it searches for and discovers promising drug and medical device candidates worldwide, incorporates them into its pipeline for development, and commercializes them in the global market. The Company focuses its research and development on a pipeline consisting of cell therapy products using human cells. Currently, it is advancing three pipelines targeting urge fecal incontinence (ICEF15), passive fecal incontinence (ICEF16), and stress urinary incontinence (ICES13).

Employees

Sector

Pharmaceuticals

Calendar

11-10 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-19	JP¥601.00	+1.52%	39,700
26-08-18	JP¥592.00	+0.17%	44,700
26-08-17	JP¥591.00	+1.90%	31,700
26-08-14	JP¥580.00	-1.36%	54,500
26-08-13	JP¥588.00	0.00%	37,700

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Stock Market
Stocks
504A Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	26.73B 167M 145M 136M 124M 233M 16.05B 236M 1.6B 626M 8.02B 629M 615M	P/E 2026 *	-7.26x	P/E 2027 *	-6.85x
Enterprise Value	26.73B 167M 145M 136M 124M 233M 16.05B 236M 1.6B 626M 8.02B 629M 615M	EV / Sales 2026 *	26.7x	EV / Sales 2027 *	24.8x
Free-Float	52.14%	Yield 2026 *	-	Yield 2027 *	-

08-06	Innovacell Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Innovacell Inc. Provides Update on ICEF15 Multi-Regional Phase III Clinical Trial Enrollment and Completion of Patient Recruitment in Japan and Europe	CI
07-30	EVERSANA Inc. Selected By Innovacell Inc. As Commercialization Partner To Advance Novel Cell Therapy ICEF15 In The United States	CI
07-23	Innovacell Inc. Announces Execution of a Product Commercialization Agreement with EVERSANA Life Science Services, LLC for the U.S. Market	CI
07-02	Innovacell Secures U.S. Clearance for Global Phase III Cell Therapy Clinical Trial	MT
07-02	Innovacell Inc Announces Completion of FDA IND Review And Approval To Include U.S. Sites And Patients In ICEF15 Multi-Regional Phase III Fidelia Trial	CI
05-13	Innovacell Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Innovacell Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2026	CI
02-24	Innovacell Inc. has completed an IPO in the amount of ¥12.319155 billion.	CI
02-23	Innovacell Forecasts Wider 2026 Loss After TSE Growth Listing	MT
02-23	Innovacell Targets Global Launch of Lead Cell Therapy After IPO	MT
02-23	Innovacell Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

1 day	+1.52%
1 week	+2.21%
Current month	+11.09%
1 month	+29.53%
3 months	-12.26%

1 week	571	609
1 month	443	609
Current year	377	1,248
1 year	377	1,248
3 years	377	1,248
5 years	377	1,248
10 years	377	1,248

Manager	Title	Age	Since
Colin Lee Novick CEO	Chief Executive Officer	45	2022-02-28
Jason Sieger CEO	Chief Executive Officer	44	2025-02-28
Yasushi Hosono DFI	Director of Finance/CFO	59	2021-06-30

Innovacell Inc. Stock

Stocks

504A

JP3147850006

Pharmaceuticals

Valuation: Innovacell Inc.

Chart: Innovacell Inc.

Latest news : Innovacell Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Innovacell Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Director	Title	Age	Since
Jason Sieger BRD	Director/Board Member	44	2020-12-31
Colin Lee Novick BRD	Director/Board Member	45	2021-06-30
Rainer Marksteiner BRD	Director/Board Member	56	2021-03-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INNOVACELL INC.	+1.52%	+2.21%	-	-	167M
ELI LILLY AND COMPANY	+3.60%	+0.88%	+75.59%	+124.32%	1,093B
JOHNSON & JOHNSON	+3.33%	+4.35%	+53.82%	+57.17%	653B
ABBVIE INC.	+3.43%	+3.53%	+25.34%	+72.45%	458B
ROCHE HOLDING AG	+0.82%	-0.38%	+39.93%	+43.18%	355B
NOVARTIS AG	+0.21%	+1.40%	+24.82%	+39.93%	294B
ASTRAZENECA PLC	+0.64%	+1.69%	+1.00%	+11.49%	248B
AMGEN INC.	+1.41%	+2.65%	+45.34%	+62.43%	230B
NOVO NORDISK A/S	-0.68%	-2.22%	-15.86%	-53.56%	203B
GILEAD SCIENCES, INC.	+3.25%	+5.65%	+21.57%	+89.04%	178B
Average	+1.74%	+1.43%	+30.17%	+49.61%	371.06B
Weighted average by Cap.	+2.41%	+1.45%	+43.68%	+68.87%

	2026 *	2027 *
Net sales	1B 6.26M 5.41M 5.09M 4.63M 8.7M 600M 8.83M 59.72M 23.4M 300M 23.52M 23.01M	1.08B 6.75M 5.83M 5.49M 4.99M 9.38M 647M 9.52M 64.38M 25.23M 324M 25.36M 24.81M
Net income	-3.46B -21.7M -18.74M -17.63M -16.02M -30.14M -2.08B -30.58M -207M -81.05M -1.04B -81.46M -79.69M	-3.81B -23.86M -20.61M -19.39M -17.62M -33.14M -2.29B -33.63M -227M -89.12M -1.14B -89.57M -87.63M
Net Debt	-	-